Developmental pharmacokinetics of etoposide in 67 children: Lack of dexamethasone effect

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 3, 2011, Pages 597-603

  Urien, Saik ^a,b,l   Doz, François ^b,c   Giraud, Carole ^a,b   Rey, Elisabeth ^a,b,d   Gentet, Jean Claude ^e   Chastagner, Pascal ^f   Vassal, Gilles ^g   Corradini, Nadège ^h   Auvrignon, Anne ⁱ   Leblond, Pierre ^j   Rubie, Hervé ^k   Treluyer, Jean Marc ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT CURIE   (France)

^d Hopital Cochin Saint Vincent de Paul ^*  (France)

^e TIMONE HOSPITAL   (France)

^f HÔPITAL D ENFANTS   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h HÔTEL DIEU   (France)

ⁱ ARMAND TROUSSEAU HOSPITAL   (France)

^j CENTRE OSCAR LAMBRET   (France)

^k HÔPITAL DES ENFANTS   (France)

^l Paris Descartes University   (France)

more..

Author keywords

Anticancer drugs; Children; Dexamethasone; Etoposide; Genetic polymorphisms; Population pharmacokinetics

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; ETOPOSIDE; ONDANSETRON; ABCB1 PROTEIN, HUMAN; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A; GLYCOPROTEIN P;

ADOLESCENT; ALLOMETRY; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; CYP3A4 GENE; CYP3A5 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; GENE; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MDR1 GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; BIOLOGICAL MODEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG INTERACTION; GENETICS; INFANT; NEOPLASM; NONLINEAR SYSTEM; PATHOLOGY;

ADOLESCENT; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; DRUG INTERACTIONS; ETOPOSIDE; HUMANS; INFANT; MODELS, BIOLOGICAL; NEOPLASMS; NONLINEAR DYNAMICS; ONDANSETRON; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79953767582     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1357-2     Document Type: Article

References (19)

1. JC Gentet F Doz E Bouffet D Plantaz H Roché P Tron C Kalifa F Mazingue E Sariban P Chastagner, et al. 1994 Carboplatin and VP 16 in medulloblastoma: a phase II Study of the French Society of Pediatric Oncology (SFOP) Med Pediatr Oncol 23 422 427 1:STN:280:DyaK2czms1eltg%3D%3D 10.1002/mpo.2950230506 8084309 (Pubitemid 24296699)
2. D Frappaz J Michon O Hartmann E Bouffet O Lejars H Rubie JC Gentet P Chastagner E Sariban L Brugiere, et al. 1992 Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study J Clin Oncol 10 1592 1601 1:STN:280:DyaK3s%2FhvFCisA%3D%3D 1403039 (Pubitemid 23057989)
3. F Pein MF Tournade JM Zucker M Brunat-Mentigny A Deville P Boutard F Dusol JC Gentet E Legall F Mechinaud, et al. 1994 Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor-a phase II study by the French Society of Pediatric Oncology J Clin Oncol 12 931 936 1:STN:280:DyaK2c3hs12nsA%3D%3D 8164044 (Pubitemid 24145319)
4. L Lumbroso-Le Rouic I Aerts C Lévy-Gabriel R Dendale X Sastre M Esteve B Asselain D Bours F Doz L Desjardins 2008 Conservative treatments of intraocular retinoblastoma Opthalmology 115 1405 1410 10.1016/j.ophtha.2007.11. 009
5. PJ Hesketh WH Harvey WG Harker TM Beck T Ryan LJ Bricker JA Kish WK Murphy JD Hainsworth B Haley 1994 A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis J Clin Oncol 12 596 600 1:STN:280:DyaK2c7msFKqtA%3D%3D 8120559 (Pubitemid 24079904)
6. MV Relling J Nemec EG Schuetz JD Schuetz FJ Gonzalez KR Korzekwa 1994 O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4 Mol Pharmacol 45 352 358 1:CAS:528:DyaK2cXitlGgtrw%3D 8114683 (Pubitemid 24063092)
7. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391 (Pubitemid 32268418)
8. SS Lakhman Q Ma GD Morse 2009 Pharmacogenomics of CYP3A: considerations for HIV treatment Pharmacogenomics 10 1323 1339 1:CAS:528:DC%2BD1MXpslOmur0%3D 10.2217/pgs.09.53 19663676
9. CM Pariante 2008 The role of multi-drug resistance p-glycoprotein in glucocorticoid function: studies in animals and relevance in humans Eur J Pharmacol 583 263 271 1:CAS:528:DC%2BD1cXjs1Squ7Y%3D
10. E Liliemark B Pettersson C Peterson J Liliemark 1995 High-performance liquid chromatography with fluorometric detection for monitoring of etoposide and its cis-isomer in plasma and leukaemic cells J Chromatogr B Biomed Appl 669 311 317 1:CAS:528:DyaK2MXntFCrtbo%3D 10.1016/0378-4347(95)00113-W 7581907
11. E Kuhn M Lavielle 2005 Maximum likelihood estimation in nonlinear mixed effects models Comput Stat Data Anal 49 1020 1030 10.1016/j.csda.2004.07.002 (Pubitemid 40710158)
12. Development Core R, Team R (2009) A language and environment for statistical computing. R Foundation for Statistical Computin, Vienna, Austria
13. L Nguyen E Chatelut C Chevreau B Tranchand I Lochon JM Bachaud A Pujol G Houin R Bugat P Canal 1998 Population pharmacokinetics of total and unbound etoposide Cancer Chemother Pharmacol 41 125 132 1:CAS:528:DyaK1cXls1Wjuw%3D%3D 10.1007/s002800050718 9443625 (Pubitemid 28096266)
14. G Freyer B Tranchand B Ligneau C Ardiet PJ Souquet I Court-Fortune R Riou P Rebattu JP Boissel V Trillet-Lenoir P Girard 2000 Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study Br J Clin Pharmacol 50 315 324 1:CAS:528:DC%2BD3cXnvV2gsLc%3D 10.1046/j.1365-2125.2000.00269.x 11012554
15. Veal GJ, Cole M, Errington J, Pearson ADJ, Gerrard M, Whyman G, Ellershaw C, Boddy AV (2009) Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer Chemother Pharmacol (on line Aug 29)
16. Palle J, Frost BM, Gustafsson G, Hellebostad M, Kanerva J, Liliemark E, Schmiegelow K, Lönnerholm G (2006) Etoposide pharmacokinetics in children treated for acute myeloid leukemia. Anticancer Drugs 17:1087-1094 (Pubitemid 44454787)
17. BJ Anderson NHG Holford 2008 Mechanism-based concepts of size and maturity in pharmacokinetics Ann Rev Pharmacol Toxicol 48 303 332 1:CAS:528:DC%2BD1cXisFynu7g%3D 10.1146/annurev.pharmtox.48.113006.094708 (Pubitemid 351738156)
18. S Kishi W Yang B Boureau S Morand S Das P Chen EH Cook GL Rosner E Schuetz CH Pui MV Relling 2004 Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia Blood 103 67 72 1:CAS:528:DC%2BD2cXhsFCqsA%3D%3D 10.1182/blood-2003-06-2105 12969965 (Pubitemid 38029919)
19. A Tran V Jullien J Alexandre E Rey F Rabillon V Girre V Dieras G Pons F Goldwasser JM Tréluyer 2006 Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms Clin Pharmacol Ther 79 570 580 1:CAS:528:DC%2BD28Xltl2msrc%3D 10.1016/j.clpt.2006.02.003 16765145 (Pubitemid 43833447)